KR20240139056A - Sars-cov-2에 의해 야기되는 감염을 예방 및/또는 치료하는 데 사용하기 위한 화합물 - Google Patents

Sars-cov-2에 의해 야기되는 감염을 예방 및/또는 치료하는 데 사용하기 위한 화합물 Download PDF

Info

Publication number
KR20240139056A
KR20240139056A KR1020247024942A KR20247024942A KR20240139056A KR 20240139056 A KR20240139056 A KR 20240139056A KR 1020247024942 A KR1020247024942 A KR 1020247024942A KR 20247024942 A KR20247024942 A KR 20247024942A KR 20240139056 A KR20240139056 A KR 20240139056A
Authority
KR
South Korea
Prior art keywords
cov
sars
oph
viral
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247024942A
Other languages
English (en)
Korean (ko)
Inventor
미레이유 라포르쥬
삐에르 그레셍
Original Assignee
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)
유니베르시떼 파리 시테
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔), 유니베르시떼 파리 시테 filed Critical 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)
Publication of KR20240139056A publication Critical patent/KR20240139056A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
KR1020247024942A 2022-01-24 2023-01-19 Sars-cov-2에 의해 야기되는 감염을 예방 및/또는 치료하는 데 사용하기 위한 화합물 Pending KR20240139056A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305072.5 2022-01-24
EP22305072 2022-01-24
PCT/EP2023/051296 WO2023139182A1 (en) 2022-01-24 2023-01-19 Compound for use in preventing and/or treating an infection caused by sars-cov-2

Publications (1)

Publication Number Publication Date
KR20240139056A true KR20240139056A (ko) 2024-09-20

Family

ID=80446266

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247024942A Pending KR20240139056A (ko) 2022-01-24 2023-01-19 Sars-cov-2에 의해 야기되는 감염을 예방 및/또는 치료하는 데 사용하기 위한 화합물

Country Status (6)

Country Link
US (1) US20250099530A1 (https=)
EP (1) EP4469073A1 (https=)
JP (1) JP2025504519A (https=)
KR (1) KR20240139056A (https=)
CN (1) CN119072326A (https=)
WO (1) WO2023139182A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2923160B1 (fr) 2007-11-02 2013-07-26 Pasteur Institut Composes destines a prevenir ou traiter une infection virale.
WO2021228846A1 (en) 2020-05-11 2021-11-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compound for preventing or treating a viral infection
WO2022008597A1 (en) * 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
WO2022123062A1 (en) * 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients

Also Published As

Publication number Publication date
EP4469073A1 (en) 2024-12-04
WO2023139182A1 (en) 2023-07-27
JP2025504519A (ja) 2025-02-12
CN119072326A (zh) 2024-12-03
US20250099530A1 (en) 2025-03-27

Similar Documents

Publication Publication Date Title
EA022303B1 (ru) Комбинации ингибиторов вируса гепатита с
Li et al. Antiviral activity of arbidol hydrochloride against herpes simplex virus I in vitro and in vivo
US20210322404A1 (en) Fgfr regulation for the treatment of viral infections
JP2023522688A (ja) ウイルス感染症の治療に使用されるａａｋ１阻害剤
US11963959B2 (en) Inhibitors for coronavirus
JP2017512837A (ja) ウイルス感染の治療または予防における使用のためのｒｎアーゼ
CN115666572A (zh) 用于预防或治疗流行性rna病毒传染病的药物组合物
US8729059B2 (en) Paramyxovirus family inhibitors and methods of use thereof
US9919034B2 (en) Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V
IL237119A (en) Heterocyclic carboxamides for the treatment of viral diseases
KR20240139056A (ko) Sars-cov-2에 의해 야기되는 감염을 예방 및/또는 치료하는 데 사용하기 위한 화합물
KR20230121767A (ko) Covid-19의 예방 및 치료를 위한 디펜히드라민 및 락토페린
US20140378502A1 (en) Par1 Inhibitors for Use in the Treatment or Prevention of Paramyxoviridae Infections
EP4281074A1 (en) Lonafarnib for use in the treatment of viral infections
Kant et al. Complete protection from SARS-CoV-2 lung infection in mice through combined intranasal delivery of PIKfyve kinase and TMPRSS2 protease inhibitors
CN105664166A (zh) 一种治疗肠道病毒感染的组合物和联合用药方法
EP3768273A1 (en) Methods and synergic compositions for treating viral infections
CN113440527B (zh) 萘酚喹或含萘酚喹的组合制剂在抗冠状病毒中的应用
AU2017210921B2 (en) Composition and combined medication method for treating enterovirus infection
Rosenwirth et al. In vivo efficacy of SDZ 35-682, a new picornavirus capsid-binding agent
TWI798578B (zh) 棘白菌素類化合物於治療黃病毒感染症的用途
TWI764284B (zh) 使用喹啉化合物來對抗冠狀病毒感染的方法
TWI917417B (zh) 治療病毒感染之方法及組合物
US20240165096A1 (en) Anti Viral Therapy
JP2009108004A (ja) 魚類生物のベータノダウイルス感染阻害剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000